Literature DB >> 33765919

Vaccinomic approach for novel multi epitopes vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

Yassir A Almofti1, Khoubieb Ali Abd-Elrahman2, Elsideeq E M Eltilib3.   

Abstract

BACKGROUND: The spread of a novel coronavirus termed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in China and other countries is of great concern worldwide with no effective vaccine. This study aimed to design a novel vaccine construct against SARS-CoV-2 from the spike S protein and orf1ab polyprotein using immunoinformatics tools. The vaccine was designed from conserved epitopes interacted against B and T lymphocytes by the combination of highly immunogenic epitopes with suitable adjuvant and linkers.
RESULTS: The proposed vaccine composed of 526 amino acids and was shown to be antigenic in Vaxigen server (0.6194) and nonallergenic in Allertop server. The physiochemical properties of the vaccine showed isoelectric point of 10.19. The instability index (II) was 31.25 classifying the vaccine as stable. Aliphatic index was 84.39 and the grand average of hydropathicity (GRAVY) was - 0.049 classifying the vaccine as hydrophilic. Vaccine tertiary structure was predicted, refined and validated to assess the stability of the vaccine via Ramachandran plot and ProSA-web servers. Moreover, solubility of the vaccine construct was greater than the average solubility provided by protein sol and SOLpro servers indicating the solubility of the vaccine construct. Disulfide engineering was performed to reduce the high mobile regions in the vaccine to enhance stability. Docking of the vaccine construct with TLR4 demonstrated efficient binding energy with attractive binding energy of - 338.68 kcal/mol and - 346.89 kcal/mol for TLR4 chain A and chain B respectively. Immune simulation significantly provided high levels of immunoglobulins, T-helper cells, T-cytotoxic cells and INF-γ. Upon cloning, the vaccine protein was reverse transcribed into DNA sequence and cloned into pET28a(+) vector to ensure translational potency and microbial expression.
CONCLUSION: A unique vaccine construct from spike S protein and orf1ab polyprotein against B and T lymphocytes was generated with potential protection against the pandemic. The present study might assist in developing a suitable therapeutics protocol to combat SARSCoV-2 infection.

Entities:  

Keywords:  B-lymphocytes; Multiepitopes vaccine; SARS CoV-2; Spike S protein; T-lymphocytes; orf1ab polyprotein

Mesh:

Substances:

Year:  2021        PMID: 33765919      PMCID: PMC7992937          DOI: 10.1186/s12865-021-00412-0

Source DB:  PubMed          Journal:  BMC Immunol        ISSN: 1471-2172            Impact factor:   3.615


  85 in total

1.  Structure validation by Calpha geometry: phi,psi and Cbeta deviation.

Authors:  Simon C Lovell; Ian W Davis; W Bryan Arendall; Paul I W de Bakker; J Michael Word; Michael G Prisant; Jane S Richardson; David C Richardson
Journal:  Proteins       Date:  2003-02-15

2.  Bimodal protein solubility distribution revealed by an aggregation analysis of the entire ensemble of Escherichia coli proteins.

Authors:  Tatsuya Niwa; Bei-Wen Ying; Katsuyo Saito; WenZhen Jin; Shoji Takada; Takuya Ueda; Hideki Taguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-27       Impact factor: 11.205

3.  Immunoinformatics approaches to design a novel multi-epitope subunit vaccine against HIV infection.

Authors:  Rajan Kumar Pandey; Rupal Ojha; Veeranarayanan Surya Aathmanathan; Muthukalingan Krishnan; Vijay Kumar Prajapati
Journal:  Vaccine       Date:  2018-03-20       Impact factor: 3.641

Review 4.  Bacterial expression systems for recombinant protein production: E. coli and beyond.

Authors:  Rachel Chen
Journal:  Biotechnol Adv       Date:  2011-09-24       Impact factor: 14.227

5.  Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens.

Authors:  K Tani; W J Murphy; O Chertov; R Salcedo; C Y Koh; I Utsunomiya; S Funakoshi; O Asai; S H Herrmann; J M Wang; L W Kwak; J J Oppenheim
Journal:  Int Immunol       Date:  2000-05       Impact factor: 4.823

Review 6.  Peptide cross-reactivity: the original sin of vaccines.

Authors:  Darja Kanduc
Journal:  Front Biosci (Schol Ed)       Date:  2012-06-01

7.  Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection.

Authors:  Mudassar Ali; Rajan Kumar Pandey; Nazia Khatoon; Aruna Narula; Amit Mishra; Vijay Kumar Prajapati
Journal:  Sci Rep       Date:  2017-08-23       Impact factor: 4.379

8.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

9.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.

Authors:  Daniel Wrapp; Nianshuang Wang; Kizzmekia S Corbett; Jory A Goldsmith; Ching-Lin Hsieh; Olubukola Abiona; Barney S Graham; Jason S McLellan
Journal:  Science       Date:  2020-02-19       Impact factor: 47.728

10.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.

Authors:  Manli Wang; Ruiyuan Cao; Leike Zhang; Xinglou Yang; Jia Liu; Mingyue Xu; Zhengli Shi; Zhihong Hu; Wu Zhong; Gengfu Xiao
Journal:  Cell Res       Date:  2020-02-04       Impact factor: 25.617

View more
  5 in total

1.  Immunoinformatic approach for the construction of multi-epitopes vaccine against omicron COVID-19 variant.

Authors:  Kanwal Khan; Salman Ali Khan; Khurshid Jalal; Zaheer Ul-Haq; Reaz Uddin
Journal:  Virology       Date:  2022-05-10       Impact factor: 3.513

Review 2.  Role of genomics in combating COVID-19 pandemic.

Authors:  K A Saravanan; Manjit Panigrahi; Harshit Kumar; Divya Rajawat; Sonali Sonejita Nayak; Bharat Bhushan; Triveni Dutt
Journal:  Gene       Date:  2022-03-04       Impact factor: 3.688

3.  A novel strategy for developing vaccine candidate against Jaagsiekte sheep retrovirus from the envelope and gag proteins: an in-silico approach.

Authors:  Nuha Amin Mahmoud; Abdelmajeed M Elshafei; Yassir A Almofti
Journal:  BMC Vet Res       Date:  2022-09-10       Impact factor: 2.792

4.  Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment.

Authors:  Suresh Kumar; Kalimuthu Karuppanan; Gunasekaran Subramaniam
Journal:  J Med Virol       Date:  2022-06-16       Impact factor: 20.693

5.  Novel multi epitope-based vaccine against monkeypox virus: vaccinomic approach.

Authors:  Shaza W Shantier; Mujahed I Mustafa; Abdelrahman H Abdelmoneim; Hiba A Fadl; Sahar G Elbager; Abdelrafie M Makhawi
Journal:  Sci Rep       Date:  2022-09-25       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.